Positive News SentimentPositive NewsNASDAQ:DYAI Dyadic International (DYAI) Stock Price, News & Analysis $1.10 -0.02 (-1.79%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.82%) As of 07/25/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dyadic International Stock (NASDAQ:DYAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dyadic International alerts:Sign Up Key Stats Today's Range$1.06▼$1.1250-Day Range$0.91▼$1.1252-Week Range$0.91▼$2.20Volume73,027 shsAverage Volume193,653 shsMarket Capitalization$33.10 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida. Read More Dyadic International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreDYAI MarketRank™: Dyadic International scored higher than 66% of companies evaluated by MarketBeat, and ranked 363rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyadic International has received no research coverage in the past 90 days.Read more about Dyadic International's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dyadic International are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyadic International is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyadic International is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyadic International has a P/B Ratio of 13.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyadic International's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.54% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dyadic International has recently decreased by 25.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyadic International does not currently pay a dividend.Dividend GrowthDyadic International does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.54% of the float of Dyadic International has been sold short.Short Interest Ratio / Days to CoverDyadic International has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dyadic International has recently decreased by 25.37%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentDyadic International has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dyadic International this week, compared to 0 articles on an average week.Search Interest5 people have searched for DYAI on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dyadic International insiders have not sold or bought any company stock.Percentage Held by Insiders29.50% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.95% of the stock of Dyadic International is held by institutions.Read more about Dyadic International's insider trading history. Receive DYAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter. Email Address DYAI Stock News HeadlinesDyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutionsJuly 2, 2025 | businesswire.comDyadic International, Inc. (DYAI) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that you don't want to take with your retirement savings.July 26 at 2:00 AM | Create New Advertiser (Ad)Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial ApplicationsJune 2, 2025 | globenewswire.comEarnings call transcript: Dyadic Q1 2025 revenue misses, stock rises 3.85%May 16, 2025 | investing.comDYAI: Fermbox Purchase OrderMay 16, 2025 | msn.comDyadic International, Inc. (DYAI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comDyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 14, 2025 | finance.yahoo.comSee More Headlines DYAI Stock Analysis - Frequently Asked Questions How have DYAI shares performed this year? Dyadic International's stock was trading at $1.75 at the beginning of 2025. Since then, DYAI shares have decreased by 37.1% and is now trading at $1.10. How were Dyadic International's earnings last quarter? Dyadic International Inc. (NASDAQ:DYAI) announced its earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.07) earnings per share for the quarter. The biotechnology company earned $0.39 million during the quarter. Dyadic International had a negative trailing twelve-month return on equity of 233.69% and a negative net margin of 163.94%. Read the conference call transcript. Who are Dyadic International's major shareholders? Dyadic International's top institutional investors include Chapin Davis Inc. (2.93%). View institutional ownership trends. How do I buy shares of Dyadic International? Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyadic International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyadic International investors own include Pfizer (PFE), Enbridge (ENB), Meta Platforms (META), Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2025Today7/26/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYAI CIK1213809 Webwww.dyadic.com Phone(561) 743-8333Fax561-743-8343Employees7Year FoundedN/APrice Target and Rating Average Price Target for Dyadic International$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+445.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.81 million Net Margins-163.94% Pretax Margin-163.77% Return on Equity-233.69% Return on Assets-59.37% Debt Debt-to-Equity Ratio5.40 Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$3.49 million Price / Sales9.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book13.75Miscellaneous Outstanding Shares30,090,000Free Float21,214,000Market Cap$33.10 million OptionableOptionable Beta0.88 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:DYAI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.